News

AddToAny

Google+ Facebook Twitter Twitter

Poliovirus therapy for recurrent glioblastoma

A genetically modified poliovirus therapy shows significantly improved long-term survival for patients with recurrent glioblastoma.

Dr. Alan Friedman Performs a Glioblastoma Biopsy at Duke University Hospital

The therapy, developed at Duke Cancer Institute in the US, has a three-year survival rate of 21% in a phase 1 clinical trial. In comparison, just 4% of patients at Duke with the same type of recurring brain tumors were alive at three years when undergoing the standard treatment.

Darell D Bigner, senior study author, said: “Glioblastoma remains a lethal and devastating disease, despite advances in surgical and radiation therapies. There is a tremendous need for fundamentally different approaches. With the survival rates in this early phase of the poliovirus therapy, we are encouraged and eager to continue with the additional studies.”

bit.ly/BS_AugNews02

Related Articles

My lab: diagnostic cytopathology and molecular

Specialist Biomedical Scientist Beth Carroll gives a guided tour of her laboratory in Cornwall.

Life in cytology (without cervical screening)

Consultant Biomedical Scientist Tracey Stevenson discusses developing a diagnostic cytology service after her previous laboratory was unsuccessful in bidding for cervical screening programme work.

Diffuse optics for diagnosticsDiffuse optics for diagnostics

Among the optics-based tools used in diagnostics, diffuse optics (DO) is rapidly emerging as one of the most attractive technologies.

Clinical andrology: overcoming barriers, improving outcomes

Clinical Scientist and Andrology Service Lead Stuart Long on the impact that taking on a patient-facing role can have.

Top